Importer of Controlled Substances Registration, 51983 [2018-22420]
Download as PDF
<![CDATA[
51983
Federal Register / Vol. 83, No. 199 / Monday, October 15, 2018 / Notices
42696, 42697 (2018). ‘‘Moreover, in the
absence of an application (whether
timely filed or not), there is nothing to
act upon.’’ Reece, 77 FR at 35055,
Rampey, 83 FR at 42697. Accordingly,
because Registrant has allowed his
registration to expire and has not filed
an application to renew his registration
or for any other registration in Alabama,
this case is now moot and will be
dismissed.
Order
Pursuant to 28 CFR 0.100(b) and the
authority thus vested in me by 21 U.S.C.
824(a), I order that the Order to Show
Cause issued to Phillip O. Rawlings, Jr.,
M.D., be, and it hereby is, dismissed.
This Order is effective immediately.
[FR Doc. 2018–22421 Filed 10–12–18; 8:45 am]
BILLING CODE 4410–09–P
The
company listed below applied to be
registered as an importer of various
basic classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
registration by the Drug Enforcement
Administration (DEA) as importers of
various classes of schedule I or II
controlled substances.
Notice of registration.
Registrant listed below have
applied for and been granted
SUMMARY:
Company
FR Docket
Galephar Pharmaceutical Research Inc .................................
83 FR 37525 ..........................................................................
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823, 952(a) and
958(a) and determined that the
registration of the listed registrant to
import the applicable basic classes of
schedule I or II controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I or II controlled substance to
the above listed company.
Dated: September 24, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–22420 Filed 10–12–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
khammond on DSK30JT082PROD with NOTICES
Dated: September 26, 2018.
Uttam Dhillon,
Acting Administrator.
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Cambrex High Point, Inc.
ACTION:
Notice of application.
VerDate Sep<11>2014
21:34 Oct 12, 2018
Jkt 247001
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before November 14, 2018. Such
persons may also file a written request
for a hearing on the application on or
before November 14, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
DATES:
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Published
August 1, 2018.
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on July 16,
2018, Cambrex High Point Inc., 4180
Mendenhall Oaks Parkway, High Point,
North Carolina 27265–8017 applied to
be registered as an importer of the
following basic classes of controlled
substances:
Controlled
substance
Drug
code
Schedule
Amphetamine ...................
Codeine ............................
Oxymorphone ...................
Noroxymorphone ..............
1100
9050
9652
9668
II
II
II
II
The company plans to manufacture
the above listed controlled substances in
bulk for distribution to its customers.
Dated: October 1, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–22416 Filed 10–12–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Specgx, LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
DATES:
E:\FR\FM\15OCN1.SGM
15OCN1
]]>Agencies
[Federal Register Volume 83, Number 199 (Monday, October 15, 2018)]
[Notices]
[Page 51983]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-22420]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Registration
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Registrant listed below have applied for and been granted
registration by the Drug Enforcement Administration (DEA) as importers
of various classes of schedule I or II controlled substances.
SUPPLEMENTARY INFORMATION: The company listed below applied to be
registered as an importer of various basic classes of controlled
substances. Information on previously published notices is listed in
the table below. No comments or objections were submitted and no
requests for hearing were submitted for these notices.
------------------------------------------------------------------------
Company FR Docket Published
------------------------------------------------------------------------
Galephar Pharmaceutical 83 FR 37525..... August 1, 2018.
Research Inc.
------------------------------------------------------------------------
The Drug Enforcement Administration (DEA) has considered the
factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the
registration of the listed registrant to import the applicable basic
classes of schedule I or II controlled substances is consistent with
the public interest and with United States obligations under
international treaties, conventions, or protocols in effect on May 1,
1971. The DEA investigated the company's maintenance of effective
controls against diversion by inspecting and testing each company's
physical security systems, verifying the company's compliance with
state and local laws, and reviewing the company's background and
history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the DEA has granted a registration as
an importer for schedule I or II controlled substance to the above
listed company.
Dated: September 24, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-22420 Filed 10-12-18; 8:45 am]
BILLING CODE 4410-09-P
